Recent

% | $
Quotes you view appear here for quick access.

Netflix, Inc. Message Board

rocketjock1 28 posts  |  Last Activity: Apr 12, 2016 12:00 AM Member since: Mar 9, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Help with Lawsuit Rosen Law Firm

    by chaseyourdream_82 Apr 11, 2016 3:39 PM
    rocketjock1 rocketjock1 Apr 12, 2016 12:00 AM Flag

    No. If you held your shares beyond the end of the class action period (August 12, 2014) but your purchase price minus $2.77 is greater than zero then you still have a loss.

    Sentiment: Strong Buy

  • Reply to

    Help with Lawsuit Rosen Law Firm

    by chaseyourdream_82 Apr 11, 2016 3:39 PM
    rocketjock1 rocketjock1 Apr 11, 2016 9:58 PM Flag

    Me too. I had to call my old 401k broker to get copies of my statements for the class action time period. Once I had those it took about 4 hours to fill out claims for two accounts. I only have a few thousand shares that I bought over $2 (bought in mid $3 range) but that still may net me $500 @ .17 per share compensation.

    Sentiment: Strong Buy

  • Reply to

    Help with Lawsuit Rosen Law Firm

    by chaseyourdream_82 Apr 11, 2016 3:39 PM
    rocketjock1 rocketjock1 Apr 11, 2016 9:45 PM Flag

    The final determination will be depend on your losses in proportion to the losses of other claimants. The initial estimate is that the average recovery will be about .17 per share. If the difference between your buy and sale price (if you did sell) is higher than the average claimants then you will get more than .17 cents. If you didn't buy shares high (like me) and sold them not much lower than you purchased them for (or didn't sell) then you will get less than .17 cents.

    Part of your share of the recovery will be in the form of shares (1/20th of your loss determination).

    Sentiment: Strong Buy

  • Reply to

    Dr. Joe Comment Regarding Two PH3 Trials...

    by gene4346 Apr 6, 2016 9:42 AM
    rocketjock1 rocketjock1 Apr 6, 2016 10:23 AM Flag

    Most definitely.

    Sentiment: Strong Buy

  • Reply to

    Dr. Joe Comment Regarding Two PH3 Trials...

    by gene4346 Apr 6, 2016 9:42 AM
    rocketjock1 rocketjock1 Apr 6, 2016 10:17 AM Flag

    I haven't researched this yet but I question his assertion that "most" drugs require multiple phase 3 trials (planned). I have not seen that any of drug trials that I've followed. My experience has been that additional ph3 trials are done only if the sponsor determines additional data is needed once the first trial completes or is stopped or if the FDA issues a CR in response to a NDA or BLA that requires a new trial. Maybe he was speaking of immunotherapy trials specifically where there hasn't been as much research, but again, I don't know of any trials where two ph3 were planned.

    Sentiment: Strong Buy

  • Reply to

    Dr. Joe Comment Regarding Two PH3 Trials...

    by gene4346 Apr 6, 2016 9:42 AM
    rocketjock1 rocketjock1 Apr 6, 2016 9:58 AM Flag

    The SPA requires a recurrence reduction of at least 38% (Hazard Ratio of .62). This is stated in the Clinical Study Protocol and was confirmed by Dr Peoples during our discussion with him last week.

    Sentiment: Strong Buy

  • Reply to

    I Think We Are Headed For $2.00

    by jimkolak Apr 4, 2016 2:06 PM
    rocketjock1 rocketjock1 Apr 4, 2016 2:36 PM Flag

    Yep, $2 soon. I think $2 is still good value for new investors who may think they missed out. True value for this stock is mid-teens and I expect we are headed there by the end of Summer as the interim report is published followed by the phase 2 Neuvax/Herceptins interim data in September. See my rNPV analysis.

    Sentiment: Strong Buy

  • Reply to

    Dr. Joseph Sinkule Conference Call

    by danindenver33 Apr 1, 2016 7:02 PM
    rocketjock1 rocketjock1 Apr 1, 2016 8:28 PM Flag

    Hi Dan -Thanks for everything you've done to help inform the Galena investment community. You've done an absolutely amazing service for all of by bringing in these knowledgeable speakers. I'm really looking forward to listening to Dr Sinkule discuss the development of Neuvax under Apthera. I know as holders of many warrants, the Apthera team still has big stake in the success of Neuvax.

    Sentiment: Strong Buy

  • Reply to

    A rNPV analysis for Galena

    by rocketjock1 Jan 11, 2016 11:37 PM
    rocketjock1 rocketjock1 Apr 1, 2016 10:51 AM Flag

    Yes, someday đŸ™‚. But an rNPV analysis is used to determine how much you should be willing to pay for a stock today...not after its product has already been approved and has been bringing in revenue.

    Sentiment: Strong Buy

  • rocketjock1 rocketjock1 Mar 31, 2016 10:12 PM Flag

    You're right, all of the warrants may not be exercised but I expect most of them will be. I think the investors that bought the share offering in January are not looking for a long-term investment and would be more in favor of a quick profit rather than taking on risk. They can sell the warrants at $1.49 for a quick 5% profit. If we reach the $1.49 level in the next couple of weeks this represents an annualized 20% return for those investors. I think they'll take the money and invest again in another company desperate for financing where they can get good terms.

    Sentiment: Strong Buy

  • rocketjock1 rocketjock1 Mar 31, 2016 10:03 PM Flag

    I was going to wait until after the Interim report comes out in June before revisiting the rNPV but I might do it sooner. There were some suggestions for improvement left on the other thread that I may incorporate into it next time.

    I agree that I left out the remaining Q1 burn for March and I also forgot the one-time charge of $4-5 mil expected in Q2. I still think the $15 mil that will be reimbursed to Galena via the B&O is going toward settlement of the Class Action and that's why I didn't include it.

    Sentiment: Strong Buy

  • For those worried about the company having to raise cash again later this year the situation is not so dire. The offering in January included warrants totaling 13,643,181 that are executable at $1.42. We will begin to see these redeemed as the stock price extends above that price. When all these warrants are redeemed, Galena will have another $19.37 million in cash. Also, now that the stock price is over $1 the Lincoln Financing deal is available which will allow the company to raise up to another $42 million in cash.

    38.2 Million cash on hand as of Feb 29 - ~14 mil burn in Q1 leaves 24.2 mil at March 31st. 24.2 + 19.37 +42 = 85.57 cash available for operations.

    At their forecasted burn rate of ~8 to 10 mil/quarter for remainder of year, this amounts to over 9 quarters of cash available. There is also the potential for the company to earn revenue from the milestone payments arranged as part of the Zuplenz/Abstral divestiture.

    Sentiment: Strong Buy

  • Reply to

    Any technical analyst out there?

    by jdpali Mar 30, 2016 12:27 PM
    rocketjock1 rocketjock1 Mar 30, 2016 12:43 PM Flag

    The warrants from the January public offering become executable at $1.42 so expect some resistance at that level.

    Sentiment: Strong Buy

  • rocketjock1 rocketjock1 Mar 24, 2016 3:27 PM Flag

    No risk no reward. Galena saw the potential that no one else saw and got the rights to develop and market Neuvax cheap. Those of us that have believed will be rewarded too.

    Sentiment: Strong Buy

  • Reply to

    Partnership

    by jimkolak Feb 22, 2016 12:43 PM
    rocketjock1 rocketjock1 Mar 11, 2016 6:03 PM Flag

    Yes. Especially since Galena is on the hook to pay MDACC a 5% royalty.

    Sentiment: Strong Buy

  • Reply to

    A Frickin' Typo.....

    by gene4346 Mar 11, 2016 3:01 PM
    rocketjock1 rocketjock1 Mar 11, 2016 3:08 PM Flag

    Blame goes to Schwartz for not running a tight ship and the person who puts their signature the 10K (the new CFO John Burns).

    From the approval page:
    I, John T. Burns, certify that:
    1. I have reviewed this Annual Report on Form 10-K of Galena Biopharma, Inc.;
    2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

    Sentiment: Strong Buy

  • rocketjock1 rocketjock1 Mar 11, 2016 2:39 PM Flag

    I have to agree with you. Things have been hard enough without compounding the problems with errors that could have been easily avoided.

    Sentiment: Strong Buy

  • Reply to

    AF Updated Tweets

    by highflier2go Mar 11, 2016 2:11 PM
    rocketjock1 rocketjock1 Mar 11, 2016 2:16 PM Flag

    A real journalist would have contacted the company's IR department before publishing such a damaging article to make sure there wasn't an error. Honestly, it was the first thing that popped into my mind that maybe the "not" had been accidentally left out.

    Sentiment: Strong Buy

  • rocketjock1 rocketjock1 Mar 11, 2016 2:09 PM Flag

    LOL. AF exposed for the idiot he is!

    Sentiment: Strong Buy

  • rocketjock1 by rocketjock1 Mar 11, 2016 2:08 PM Flag

    Because of the AF hit piece today, I think this is a good time to bring attention to what Mark Schwartz told me at the Shareholders Meeting last June. From my above notes, Mark's response to my question on competing with Insys:

    " We do not want to emulate what Insys has done. They (Insys) are under various investigations including the OIG. We want to grow the right way and build long-lasting, respected relationships with our customer base."

    I did not lead Mark in any way to make that statement and I sincerely believe that he meant what he said. At this point, as far as the investigation tied to the two doctors in Alabama is concerned, I am comfortable that the investigation will not turn up in wrong-doing by Galena as far Illegal kick-backs are concerned. Keep in mind that many municipalities are hurting for revenue right now, and many state and federal investigators are looking for any "smoke" to see if there are any real fires that they can prosecute and find revenue for their departments. AF put out this "story" within hours of the 10K being issued. It's very fishy that out of the whole universe of stocks that he follows that he "discovered" this "burning issue" so quickly after the 10K publication. No question, this was a pre-meditated attack on his part and his henchmen. And then for extra effect, he speculates, without supporting evidence, that the company may have intentionally delayed notification of being a target of investigation until after completion of the secondary offering. I hope to live to see the day that this guy is put in jail.

    See my June 21, 2015 post on Annual Shareholder Meeting for the original meeting notes.

    Sentiment: Strong Buy

NFLX
90.79-0.75(-0.82%)May 4 4:00 PMEDT